ROCKVILLE, Md.--(BUSINESS WIRE)--
Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report
financial results for full year 2008 on Thursday, March 5, 2009, after
market close.
Company management will host a conference call at 5:00 pm Eastern on
March 5, 2009 to discuss these financial results, recent business
developments and the outlook for 2009. The conference call will be
accessible by dialing 888/679-8037 or 617/213-4849
(international) and providing passcode 51068666. A webcast of the
conference call will be accessible from the Company’s website at www.emergentbiosolutions.com,
under “Investors”.
Emergent BioSolutions is offering call participants a pre-registration
option that expedites access to the call and minimizes hold times.
Pre-registrants will be issued a pin number to be used when dialing into
the live call which will provide quick access to the conference call by
bypassing the operator upon connection. Pre-registration, while not
mandatory, can be accessed using the following website: https://www.theconferencingservice.com/prereg/key.process?key=PJU79TK8J.
A replay of the conference call will be accessible, approximately one
hour following the conclusion of the call, by dialing 888/286-8010 or
617/801-6888 and using the passcode 53418383. The replay will be
available through March 19. The webcast will be archived on the
company’s website, www.emergentbiosolutions.com,
under “Investors”.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of immune-related
biologic products, consisting of vaccines and therapeutics that assist
the body’s immune system to prevent or treat disease. Emergent’s
marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is
the only vaccine approved by the U.S. Food and Drug Administration for
the prevention of anthrax infection. Emergent’s development pipeline
includes programs focused on anthrax, botulism, typhoid, tuberculosis,
hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.
Source: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
Investors Contact:
Robert G.
Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media
Contact:
Tracey Schmitt
Director, Corporate Communications
301-795-1800
SchmittT@ebsi.com
